ENXTAM:PHARMBiotechs
Pharming Group (ENXTAM:PHARM) Valuation After 27% Revenue Beat And Joenja Growth Outlook
Why Pharming Group’s latest revenue update is getting attention
Pharming Group (ENXTAM:PHARM) has drawn fresh investor interest after reporting preliminary 2025 revenues about 27% above its own guidance, alongside a 2026 sales outlook tied to Joenja and upcoming clinical trial read outs.
See our latest analysis for Pharming Group.
The preliminary 2025 revenue update appears to have come on the back of building momentum in the share price, with a 30 day share price return of 18.82% and a 90...